Literature DB >> 18418413

Gene therapy progress and prospects cancer: oncolytic viruses.

T-C Liu1, D Kirn.   

Abstract

The past 2 years have seen several major advances in oncolytic virotherapy. Studies on the interaction between viruses, immune responses and tumor microenvironment have provided important insight, while clinical trials have shown promise. This review summarizes key findings in this field over the past 2 years, and provides directions for future success.

Entities:  

Mesh：

Year:  2008        PMID： 18418413     DOI： 10.1038/gt.2008.72

Source DB:  PubMed          Journal:  Gene Ther        ISSN： 0969-7128            Impact factor:   5.250


  67 in total

Review 1.  The good viruses: viral mutualistic symbioses.

Authors:  Marilyn J Roossinck
Journal:  Nat Rev Microbiol       Date:  2011-01-04       Impact factor: 60.633

2.  Highly efficient tumor transduction and antitumor efficacy in experimental human malignant mesothelioma using replicating gibbon ape leukemia virus.

Authors:  S Kubo; M Takagi-Kimura; C R Logg; N Kasahara
Journal:  Cancer Gene Ther       Date:  2013-11-08       Impact factor: 5.987

3.  Hypoxia-regulated overexpression of soluble VEGFR2 controls angiogenesis and inhibits tumor growth.

Authors:  Guillaume Collet; Nathalie Lamerant-Fayel; Magdalena Tertil; Bouchra El Hafny-Rahbi; Jacek Stepniewski; Alan Guichard; Alexandra Foucault-Collet; Krzysztof Klimkiewicz; Stéphane Petoud; Agata Matejuk; Catherine Grillon; Alicja Jozkowicz; Jozef Dulak; Claudine Kieda
Journal:  Mol Cancer Ther       Date:  2013-10-29       Impact factor: 6.261

4.  Engineering of Brome mosaic virus for biomedical applications.

Authors:  Ibrahim Yildiz; Irina Tsvetkova; Amy M Wen; Sourabh Shukla; M Hema Masarapu; Bogdan Dragnea; Nicole F Steinmetz
Journal:  RSC Adv       Date:  2012-01-23       Impact factor: 3.361

5.  Advances in the mechanisms of action of cancer-targeting oncolytic viruses.

Authors:  Cun-Zhi Lin; Gui-Ling Xiang; Xin-Hong Zhu; Lu-Lu Xiu; Jia-Xing Sun; Xiao-Yuan Zhang
Journal:  Oncol Lett       Date:  2018-01-19       Impact factor: 2.967

6.  Enhanced antitumor effects of an engineered measles virus Edmonston strain expressing the wild-type N, P, L genes on human renal cell carcinoma.

Authors:  Xin Meng; Takafumi Nakamura; Toshihiko Okazaki; Hiroyuki Inoue; Atsushi Takahashi; Shohei Miyamoto; Gaku Sakaguchi; Masatoshi Eto; Seiji Naito; Makoto Takeda; Yusuke Yanagi; Kenzaburo Tani
Journal:  Mol Ther       Date:  2010-01-05       Impact factor: 11.454

7.  Analysis of adenovirus trans-complementation-mediated gene expression controlled by melanoma-specific TETP promoter in vitro.

Authors:  Alessandra Curioni Fontecedro; Verena Lutschg; Ossia Eichhoff; Reinhard Dummer; Urs F Greber; Silvio Hemmi
Journal:  Virol J       Date:  2010-07-29       Impact factor: 4.099

8.  Oncolytic virotherapy for osteosarcoma using midkine promoter-regulated adenoviruses.

Authors:  M Takagi-Kimura; T Yamano; M Tagawa; S Kubo
Journal:  Cancer Gene Ther       Date:  2014-02-28       Impact factor: 5.987

9.  Oncolytic adenovirus mediated Survivin knockdown by RNA interference suppresses human colorectal carcinoma growth in vitro and in vivo.

Authors:  Wei Shen; Chun-Yi Wang; Xue-Hu Wang; Zhong-Xue Fu
Journal:  J Exp Clin Cancer Res       Date:  2009-06-15

10.  Oncolytic vaccinia therapy of squamous cell carcinoma.

Authors:  Zhenkun Yu; Sen Li; Peter Brader; Nanhai Chen; Yong A Yu; Qian Zhang; Aladar A Szalay; Yuman Fong; Richard J Wong
Journal:  Mol Cancer       Date:  2009-07-06       Impact factor: 27.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.